North America Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By End Use (Diagnostic Laboratories, Hospitals & Clinics, and Others), By Type, By Country and Growth Forecast, 2024 - 2031

The North America Tuberculosis Diagnostics Market would witness market growth of 4.1% CAGR during the forecast period (2024-2031).

The US market dominated the North America Tuberculosis Diagnostics Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $635.4 million by 2031. The Canada market is experiencing a CAGR of 6.3% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 5.4% during (2024 - 2031).



The market represents a critical segment of the healthcare industry, as the fight against tuberculosis (TB) remains a top public health priority. Mycobacterium tuberculosis is the causative agent of tuberculosis, an infectious disease that attacks the lungs as its primary site of infection. Despite the fact that it is both preventable and curable, tuberculosis continues to be one of the leading causes of death, particularly in countries with poor and middle incomes.

Digital platforms can facilitate the collection and sharing of diagnostic data across healthcare systems, improving coordination and ensuring patients receive appropriate care throughout their treatment journey. In order to develop diagnostic instruments that are both adaptable and effective in a variety of healthcare environments, companies are increasingly investing in research and development. This focus on innovation is essential for overcoming the challenges associated with TB diagnosis and ensuring that all patients, regardless of where they live, have access to the best possible care.

In Mexico, the rising demand for tuberculosis diagnostics is influenced by the country’s efforts to combat TB in regions with high poverty levels and inadequate healthcare infrastructure. In 2021, there were 17 new tuberculosis cases per 100,000 population in Mexico. In 2019, the overall tuberculosis mortality rate (age-adjusted and per 100,000 population) was 1.6 (0.9 in women and 2.4 in men). The nation has been striving to incorporate more sophisticated diagnostic methods, including molecular tests and rapid diagnostic tools, into its national tuberculosis program, with a particular emphasis on rural and underserved regions where conventional diagnostic methods may not be adequate. Thus, the North American market is poised for continued growth as these nations intensify their efforts to eliminate tuberculosis and address the specific needs of their populations.

Based on End Use, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, and Others. Based on Type, the market is segmented into Detection of Latent Infection (Skin Test & IGRA), Phage Assay, Detection of Drug Resistance (DST), Nucleic Acid Testing, Radiographic Method, Cytokine Detection Assay, Diagnostic Laboratory Methods, and Other Methods. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled

• Abbott Laboratories
• Qiagen N.V
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company
• F.Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• Bruker Corporation

Market Report Segmentation

By End Use

• Diagnostic Laboratories
• Hospitals & Clinics
• Others

By Type

• Detection of Latent Infection (Skin Test & IGRA)
• Phage Assay
• Detection of Drug Resistance (DST)
• Nucleic Acid Testing
• Radiographic Method
• Cytokine Detection Assay
• Diagnostic Laboratory Methods
• Other Methods

By Country

• US
• Canada
• Mexico
• Rest of North America